FDA staff cites safety issues for Lilly, Incyte's rheumatoid arthritis drug
April 19, 2018 at 08:15 AM EDT
April 19 (Reuters) - The U.S. Food and Drug Administration staff on Thursday flagged concerns about potentially fatal blood clots from higher doses of Eli Lilly and Co and Incyte Corp's rheumatoid arthritis drug.